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Abstract
Background: We evaluated whether pre- and mid-treatment metabolic tumor volume (MTV) predicts per lesion
local recurrence (LR) in patients treated with definitive radiation therapy (RT, dose≥60 Gy) for locally advanced non-
small cell lung cancer (NSCLC).
Methods: We retrospectively reviewed records of patients with stage III NSCLC treated from 2006 to 2018 with pre-
and mid-RT PET-CT. We measured the MTV of treated lesions on the pre-RT (MTVpre) and mid-RT (MTVmid) PET-CT.
LR was defined per lesion as recurrence within the planning target volume. Receiver operating characteristic (ROC)
curves, cumulative incidence rates, and uni- and multivariable (MVA) competing risk regressions were used to
evaluate the association between MTV and LR.
Results: We identified 111 patients with 387 lesions (112 lung tumors and 275 lymph nodes). Median age was 68
years, 69.4% were male, 46.8% had adenocarcinoma, 39.6% had squamous cell carcinoma, and 95.5% received
concurrent chemotherapy. Median follow-up was 38.7 months. 3-year overall survival was 42.3%. 3-year cumulative
incidence of LR was 26.8% per patient and 11.9% per lesion. Both MTVpre and MTVmid were predictive of LR by ROC
(AUC = 0.71 and 0.76, respectively) and were significantly associated with LR on MVA (P = 0.004 and P = 7.1e-5,
respectively). Among lesions at lower risk of LR based on MTVpre, higher MTVmid was associated with LR (P = 0.001).
Conclusion: Per-lesion, larger MTVpre and MTVmid predicted for increased risk of LR. MTVmid was more highly
predictive of LR than MTVpre and if validated may allow for further discrimination of high-risk lesions at mid-RT
informing dose painting strategies.
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Introduction
Lung cancer remains the second most commonly di-
agnosed malignancy among both men and women
and is the number one cause of cancer related death
[1]. Approximately a third of patients with non-small
cell lung cancer (NSCLC) are diagnosed with stage III
disease [2, 3], which is commonly treated with defini-
tive chemoradiation and has a median overall survival
of approximately 24 months [3]. Encouragingly, a re-
cent phase III trial has shown the addition of adju-
vant durvalumab offers a benefit in overall survival
[4]. As systemic therapies improve and potentially
eradicate distant micrometastases, highly effective
local treatments may become increasingly crucial.
Definitive chemoradiation is the standard of care treat-
ment for unresectable stage III NSCLC, but a large pro-
portion of patients will experience local recurrence after
definitive local treatment. The standard dose arm from
the RTOG 0617 trial (60 Gy) showed a local recurrence
rate of 16.3 and 30.7% at one and 2 years, respectively,
and dose escalation to 74 Gy did not improve locoregio-
nal control [3].
Several groups have investigated the utility of 18F-FDG
PET-CT (PET-CT) in identifying patients and specific
lesions at high risk of treatment failure as they may
benefit from a more individualized dose strategy with
high-risk lesions receiving dose escalation and low-risk
lesions receiving dose de-escalation [5–11]. As a method
of quantifying the volume of metabolically active cancer,
there has been interest in delineating the metabolic
tumor volume (MTV, units cc) on PET imaging.
Methods to calculate MTV include gradient based
methods, which identify the edge of the metabolically ac-
tive lesion by finding the location of highest signal gradi-
ent, and threshold based methods which include all
voxels within a volume having SUV higher than a de-
fined threshold. Gradient based methods have been re-
ported as having better correlation with pathologic
findings [12]. We previously reported that higher pre-RT
MTV (sum of all lesions) was associated with local re-
currence, but other pre-RT PET parameters were not,
including maximum SUV and total lesion glycolysis
(MTV multiplied by the target volume average SUV)
[13]. Ohri et al. identified and validated per-lesion, pre-
RT MTV as a predictor of local recurrence [11]. In a
subsequent small prospective study, they showed that
dose-painted RT with conventional radiation (65 Gy) to
high-risk lesions and de-escalation (52.5–57 Gy) to low-
risk lesions yields low rates of local recurrence in high-
risk (9%) and low-risk (3%) lesions [14].
Beyond pre-RT imaging, PET-CT scans collected in
the middle of radiation treatment (mid-RT PET-CT)
may assess initial treatment response and provide add-
itional discrimination of high-risk lesions at a time when
the treatment plan can be adapted [9, 13, 15]. In a recent
phase II trial, target areas with residual metabolic activ-
ity on mid-RT PET-CT were selectively boosted, with
the patients having a promising local recurrence rate of
18% at 2 years [15]. While a prior study from our group
showed that mid-RT MTV of the entire target volume,
including primary tumor and involved lymph nodes, is
correlated with local recurrence, to our knowledge, no
group has studied whether per-lesion mid-RT MTV is
associated with local recurrence [13].
At our institution we routinely obtain both pre- and
mid-RT PET-CT for stage III NSCLC patients. Using in-
stitutional data, we sought to externally validate the find-
ings of Ohri et al. regarding pre-RT per-lesion PET
appearance, and extend them to mid-RT PET [11].
Therefore, we investigated per-lesion, pre- and mid-RT
MTV as biomarkers of local recurrence for these pa-
tients, and to our knowledge, report the largest study of
this kind.
Material and methods
Patients
With institutional review board (IRB) approval, we con-
ducted a retrospective review of our institutional data-
base for all patients with stage III (AJCC 7th edition)
non-small cell lung cancer who received definitive radi-
ation (RT, dose≥60 Gy) from June 2006–March 2018
(n = 210) and had pre- and mid-RT PET-CT scans. Mid-
RT PET-CTs were performed around halfway through
RT. Patients who received surgical resection or induc-
tion chemotherapy were excluded. Two patients who re-
ceived adjuvant durvalumab were excluded. Patients
enrolled on the RTOG 1106 trial were excluded
(NCT01507428). This left 111 patients who met our in-
clusion criteria.
Treatment and follow up
We have previously described our institutional treatment
protocol [13]. Patients received staging in concordance
with the National Cancer Center Network guidelines,
usually with confirmation of nodal involvement by endo-
bronchial ultrasound-guided fine needle aspiration. Only
ultrasound-suspicious nodes were biopsied, as opposed
to comprehensive sampling of all nodal stations. For ra-
diation planning, patients underwent PET-CT simula-
tion with 4D-CT. After confirming patients had serum
glucose < 180 mg/dL, they received 12–18mCi 18F-FDG
45–60min prior to their scan. Before 2013, PET-CT
scans were performed on a GE scanner (Milwaukee, WI)
with PET data reconstructed with an ordered set expect-
ation maximization algorithm. Subsequently, PET-CT
scans were performed on a Siemens Biograph mCT
scanner (Siemens, Erlangen, Germany) with PET data
reconstructed with time-of-flight using point-spread
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function modeling. Primary and nodal gross tumor vol-
umes (GTV) were delineated with expansion to internal
target volumes (ITV) based on 4D-CT motion. There
was no explicit GTV to clinical target volume (CTV) ex-
pansion to cover microscopic spread, as most patients
were treated with modest dose intensification and the
natural dose fall-off provided some coverage for micro-
scopic spread. Elective nodal irradiation was not per-
formed. A final expansion margin was added to the ITV
to generate the PTV, generally 5 mm. Plans were nor-
malized to obtain 95% coverage of the PTV with 100%
of the prescription dose. Patients in this cohort who re-
ceived radiation concurrent with systemic therapy most
often received weekly carboplatin and paclitaxel. Radi-
ation was delivered via intensity modulated radiation
therapy (IMRT) with 6 MV photons using multiple static
fields (typically 6–7 fields) or volume modulated arc
therapy (VMAT). Daily kV orthogonal films were used
for alignment. Patients underwent mid-RT PET-CT im-
aging halfway through treatment.
Patients were seen in follow up visits at 3-month inter-
vals during the first 2 years after RT with CT or PET-CT
imaging performed at each visit and as indicated there-
after. Per institutional standard practice, three-month
post-treatment scan was usually a PET/CT, and subse-
quent imaging was with contrast-enhanced chest CT,
with PET-CT ordered only for abnormal findings on
CT. Esophageal and pulmonary toxicities were scored
according to the National Cancer Institute Common
Terminology Criteria for Adverse Events (NCI CTCAE)
version 4.03.
PET analysis
Each primary tumor or nodal target encompassed within
an individually distinct PTV was labeled for comparison
between pre-RT and mid-RT PET-CT imaging. PET
Edge, a gradient-based method included in MIM soft-
ware (Cleveland, OH), was used to delineate treated le-
sions (lung tumors and regional lymph nodes) and
measure metabolic tumor volume on pre-RT (MTVpre)
and mid-RT (MTVmid) PET-CTs [12]. ΔMTV was de-
fined as (MTVmid-MTVpre)/MTVpre. The distributions of
MTVpre and MTVmid were right-skewed and so were log
transformed for analysis. The companion CT was used
to help identify cancerous lesions but was not directly
used to delineate the MTV.
Local recurrence
We scored local recurrence (LR) based on biopsy con-
firmation or according to the following radiographic cri-
teria occurring within the prescription dose planning
target volume (PTV):
1. Mass-like increase in size by CT
2. Increased FDG uptake in a focal rather than diffuse
pattern.
As patients received surveillance imaging as permitted
by provider preference and medical insurance, there was
variation in surveillance imaging type and quality. Thus,
rather than using a specific absolute or percentage
change, we defined significant interval change as that
which is beyond the threshold for technical scan vari-
ation similar to methods employed by other groups [6].
In scoring local recurrences according to radiographic
criteria, when available, we did not apply these criteria
to isolated imaging scans but evaluated findings in the
context of progression on serial imaging or in combin-
ation with recurrence in other sites. Out-of-field recur-
rence was defined as tumor regrowth outside of the
prescription dose radiation volume (i.e., any recurrence
that was not a LR by our definition).
Statistical analysis
Median follow up was calculated using the reverse
Kaplan-Meier method. Receiver operating characteristic
(ROC) curves, adjusted for the competing risk of death
were constructed using the R package ‘timeROC’ [16].
The R package ‘maxstat’ was used to determine optimal
thresholds for the outcome LR with bootstrap resam-
pling [17]. The cumulative incidence of LR was adjusted
for the competing risk of death. When measuring the
cumulative incidence of LR per patient, any LR was con-
sidered an event. We adjusted for baseline characteristics
in multivariable analyses (MVA) using forward selection
for patient factors meeting significance of P< 0.05 on
univariable analysis. As the data had a clustered struc-
ture with multiple target lesions per patient, MVA was
performed using competing risk regression for clustered
data using the R package ‘crrSC’ [18]. Statistical analysis
was performed using R version 3.6 (Vienna, Austria). All
p-values were two-sided and considered significant at
P < 0.05.
Results
We identified 111 patients with 387 lesions (112 lung tu-
mors and 275 lymph nodes). Median follow-up was 38.7
months (range, 0.1–109.2 months). As demonstrated in
Table 1, patients had median age 68 years, 69.4% were
male, 46.8% had adenocarcinoma, and 39.6% had squa-
mous cell carcinoma. 95.5% received concurrent chemo-
therapy with 78.4% (n = 87) receiving concurrent
carboplatin/paclitaxel (Supplemental Data). Median radi-
ation dose was 66 Gy (range, 60–74 Gy) and median
dose per fraction was 2 Gy (range, 1.8–3 Gy). The most
common schedule was 66 Gy in 30 fractions (n = 36).
Mid-RT PET-CT was obtained at a median dose of 34
Gy (interquartile range [IQR], 30–36 Gy) or at a median
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proportion of total dose of 50% (IQR, 46–55%). Primary
tumor lesions were significantly larger than lymph node
lesions when measured on pretreatment PET (median
MTVpre of 25.2 vs 1.5 cc, respectively, P < 0.0001) and
mid-treatment PET (median MTVmid of 14.5 and 0.8 cc,
respectively, P < 0.0001).
Overall survival (OS) was 72.7% (95% CI = 63.1–
80.2%) at 1 year, 54.5% (95% CI = 43.7–64.1%) at 2
years, and 42.3% (95% CI = 31.3–52.9%) at 3 years
(Fig. 1a). Median survival was 25.6 months. Cumula-
tive incidence of non-cancer death was 11.2%
(95%CI = 6.5–15.9%) at 3 years (Supplemental Figure
1). Cumulative incidence of LR per patient adjusted
for the competing risk of death was 26.8% at 3 years
(Fig. 1b, 95%CI = 18.4–35.2%). Excluding the five pa-
tients who did not receive concurrent chemotherapy,
there was a very similar 3-year LR rate of 27.2%
(95% = 18.2–36.1%). When scoring LR, 20 of 28 pa-
tients (71.4%) had pathologic evidence of recurrence
with the remainder being scored by radiographic cri-
teria alone (see Materials and Methods). Cumulative
incidence of LR per target lesion adjusted for the
competing risk of death for the entire cohort was
11.9% at 3 years (Fig. 1c, 95%CI = 10.2–13.6%) and
was 11.4% (95% = 9.6–13.2%) for those that received
concurrent chemotherapy. Figure 2 shows a repre-
sentative patient demonstrating our method of meas-
uring MTV on a per lesion basis. This patient
experienced a complete response at a nodal target
with a small MTVmid and a LR at the primary tumor
lesion with a large MTVmid. For patients who experi-
enced LR, 10 of 28 (35.7%) experienced isolated LR
without distant metastasis. No patient developed LR
prior to observed distant recurrence, and 10 patients
developed LR concurrent with discovery of distant
Table 1 Baseline patient characteristics
Parameter Cohort (n = 111)
Median age 68 (42–90) years
Male 77 (69.4%)
ECOG PS
0 13 (11.7%)
1 70 (63.1%)
2 26 (23.4%)
3 2 (1.8%)
Stage
IIIA 60 (54.1%)
IIIB 51 (45.9%)
Histology
Adenocarcinoma 52 (46.8%)
Squamous Cell Carcinoma 44 (39.6%)
Large Cell 3 (2.7%)
Adenosquamous 2 (1.8%)
NOS 10 (9.0%)
Median RT dose 66 (60–74) Gy
60–66 Gy 84 (75.7%)
> 66–74 Gy 27 (24.3%)
Concurrent chemotherapy 106 (95.5%)
Median follow up, months 38.7 (0.1–109.2)
Abbreviations: ECOG PS performance score, NOS not otherwise specified
* Continuous variables are shown with range and categorical variables with
percentages in parenthesis
Fig. 1 a. Overall survival for 111 patients with locally advanced NSCLC. b. Cumulative incidence of any progression (green-dased curve), out-of-
field recurrence (blue curve), and local recurrence per patient (red-dashed curve). c. Cumulative incidence of per-lesion local recurrence for
primary tumor and nodal target volumes receiving definitive radiation
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metastases (15.6% of patients with distant
recurrence).
We sought to determine whether MTVpre, MTVmid
or both were associated with LR. By ROC, MTVmid
(AUC = 0.76) had a slightly higher AUC value than
MTVpre (AUC = 0.71) at 3 years post-treatment ad-
justed for the competing risk of death (Fig. 3a). We
next performed univariable competing risk regression
adjusted for the competing risk of death and within-
patient clustered data, and found MTVpre, MTVmid,
and lesion location (lung primary versus lymph node)
were significantly associated with local recurrence
while histology and ΔMTV were not (Table 2). Be-
cause MTVpre and MTVmid are collinear variables, we
performed two MVAs selecting either MTVpre or
MTVmid as the MTV variable. When adjusting for le-
sion location in MVA, we observed that MTVpre
(HR = 2.01, 95% CI = 1.25–3.23, P = 0.004) and
MTVmid (HR = 2.12, 95% CI = 1.47–3.08, P = 7.1e-5)
were significantly associated with LR (Table 2). Lesion
Fig. 2 Representative patient example demonstrates per-lesion method of measuring MTV on fused PET-CT images. As shown, a nodal lesion had
a complete response to chemoradiation while the primary tumor had large residual MTV at mid-radiation PET-CT with subsequent
local recurrence
Fig. 3 a. Competing risk ROC for MTVpre (AUC = 0.71) and MTVmid (AUC = 0.76) predicting local recurrence, adjusted for competing risk of death
at 3-years post-treatment. b. Cumulative incidence of local recurrence by MTVpre size quartiles. c. Cumulative incidence of local recurrence
stratified by MTVpre ≥ 25 and < 25 cc . d. Cumulative incidence of local recurrence by MTVmid size quartiles. e. ROC for MTVmid predicting local
recurrence, adjusted for competing risk of death for the subset with MTVpre ≥ 25 cc (AUC = 0.47) and the subset with MTVpre < 25 cc (AUC = 0.66)
36 months post-treatment. f. Cumulative incidence of local recurrence for all lesions with MTVpre < 25 cc showing those with MTVmid ≥ 13.5 cc
versus < 13.5 cc have 24-month LR rates of 24.5% versus 5.3%, respectively
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location was not associated with LR in either multi-
variable model.
As demonstrated in Fig. 3b, lesions with larger MTVpre
had a higher risk of LR. When performing threshold ana-
lysis for MTVpre using the log-rank statistic for the out-
come LR, we obtained an optimal value of ≥25.4 cc
(95%CI = 5.77–42.52 cc, 1000 bootstrap resampling). We
obtained the same threshold when excluding the 5 cases
that received RT alone. Intriguingly, this value was nearly
identical to that reported by Ohri et al., and we selected the
validated 25 cc threshold for further analysis (there were no
lesions with MTVpre between 25.0 and 25.4 cc) [11]. We
observed the 3-year cumulative incidence of LR per lesion
was 6.4% versus 36.0% for lesions with MTVpre < 25 cc ver-
sus ≥25 cc, respectively (Fig. 3c, P = 7.5e-11).
Investigating the relationship between MTVmid and LR
similarly demonstrated that lesions with larger MTVmid
had a higher risk of LR (Fig. 3d). When performing
threshold analysis for MTVmid using the log-rank statis-
tic for the outcome LR, we obtained an optimal value of
≥13.5 cc (95%CI = 0.00–24.85 cc, 1000 bootstrap
resampling).
As an exploratory analysis, we assessed the predictive
value of MTVmid among the high- and low-risk subsets
defined by Ohri et al. and from our results, i.e. lesions
with MTVpre ≥ 25 cc and MTVpre < 25 cc, respectively.
On univariable analysis, MTVmid remained predictive of
LR for the subgroup of lesions with MTVpre < 25 cc
(AUC = 0.66) but not for lesions with MTVpre ≥ 25 cc
(AUC = 0.47; Fig. 3e). Among lesions with MTVpre < 25
Table 2 Univariable and multivariable competing risk regression accounting for clustered analysis and competing risk of death
Local recurrence (n = 45 events)
Variable Univariable MVA1 MVA2
Age HR 1.00
95% CI 0.96–1.05
P 0.84
ΔMTV HR 1.09
95% CI 0.96–1.24
P 0.19
Log(MTVpre) HR 2.43 2.01
95% CI 1.56–3.78 1.25–3.23
P 8.4e-5 0.004
Log(MTVmid) HR 2.33 2.12
95% CI 1.61–3.37 1.47–3.08
P 6.8e-5 7.1e-5
Primary Lesion (non-nodal target) HR 3.60 1.37 1.79
95% CI 1.86–6.95 0.67–2.79 0.86–3.72
P 0.0001 0.38 0.12
RT dose HR 1.06
95% CI 0.97–1.16
P 0.17
Histology
Adenocarcinoma (ref) HR –
95% CI –
P –
SCC HR 1.89
95% CI 0.80–4.46
P 0.15
All others HR 1.27
95% CI 0.30–5.45
P 0.75
Abbreviations: MVA multivariable analysis; MTVpre pretreatment metabolic tumor volume; MTVmid mid-treatment metabolic tumor volume; RT radiation therapy;
SCC squamous cell carcinoma; ref. reference
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cc, cumulative incidences of local recurrence for lesions
with MTVmid < 13.5 cc and MTVmid ≥ 13.5 cc were 5.3
and 24.5% at 3 years, respectively (Fig. 3f). In the subset
of lesions with MTVpre < 25 cc, increasing MTVmid was
significantly associated with higher risk of LR (HR =
1.92, 95% CI = 1.28–2.28, P = 0.002). In the subset of
lesions with MTVpre ≥ 25 cc, MTVmid was no longer sig-
nificantly associated with higher risk of LR (Supplemen-
tal Tables 1 and 2).
Toxicity
Fifty-three (47.7%) patients experienced grade ≥ 2 pul-
monary or esophageal toxicity including 44 cases of
grade 2 esophagitis, 16 cases of grade 2 radiation pneu-
monitis, 1 case of grade 3 esophagitis, 3 cases of grade 3
radiation pneumonitis, and 1 case of grade 5 radiation
pneumonitis
Discussion
In this study, we report per-lesion outcomes for patients
with stage III NSCLC following definitive chemoradia-
tion, and we show that MTVpre and MTVmid predict
per-lesion LR. These findings externally validate the re-
sults of Ohri et al., and extend them to mid-treatment
imaging [11]. We focused on MTV rather than other
PET parameters because we previously observed that
only pre-RT MTV had a significant association with LR
as compared to other PET parameters including max-
imum SUV and total lesion glycolysis [13]. Additionally,
we did not previously find association between LR and
mid-RT maximum SUV or the ratio of mid-RT max-
imum to the pre-RT value.
Previous efforts to intensify locoregional treatment
have been unsuccessful, as seen with RTOG 0617, which
demonstrated increased toxicity without a local control
benefit when uniform RT dose escalation was applied to
all target volumes [3]. However, recent retrospective and
prospective studies have demonstrated the feasibility of
adapting dose to individual lesions, which may allow for
dose escalation and de-escalation of lesions at high and
low risk of LR, respectively [11, 15]. Reliable prognostic
factors of which lesions are most likely to recur and
therefore benefit from treatment intensification remain
to be determined but PET-CT based metrics are promis-
ing. Prospective studies, including RTOG 1106
(NCT01507428), are evaluating dose escalation of FDG-
avid lesions on mid-RT PET-CT [15]. Other prospective
trials tailor either dose escalation of the primary tumor
or region inside the primary tumor with > 50% SUVmax
on pre-RT PET-CT (NCT01024829), or de-escalation of
lesions with MTVpre < 25 cc [14, 19, 20]. We have previ-
ously demonstrated the prognostic ability of total tumor
mid-RT PET-CT parameters in predicting locoregional
or distant progression, and others have shown an
association between mid-RT PET-CT and overall sur-
vival [13, 21]. Our current findings lend support to using
mid-RT PET-CT for adaptive RT strategies to primary
lung tumors and/or regional lymph nodes on a per-
lesion level.
We observed a per-patient cumulative incidence of LR
of 26.8% at 3 years when accounting for the competing
risk of death, an important consideration due to the
poor prognosis of patients with stage III lung cancer.
Our median overall survival of 25.6 months is compar-
able to the rate reported by others, suggesting our co-
hort has a comparable observation period for LR with
similar competing risk of death [3, 15, 22]. Overall, our
LR rates are similar to or better than those reported in
the literature with estimates ranging from 18 to 31% [3,
6, 11, 22]. This improvement is notable in light of the
smaller tumor margins that we use without explicit ex-
pansion for microscopic extension (CTV =GTV), and
may be explained by our routine use of 4D CT and
PET-CT simulation, daily image-guidance, respiratory
motion management as indicated, and modestly esca-
lated prescription doses.
When analyzed per lesion, we find that both larger
MTVpre and MTVmid are predictive of increased risk of
LR. We externally validated findings by Ohri et al. in
showing a threshold of MTVpre ≥ 25 cc has high specifi-
city in predicting recurrence (albeit with a wide confi-
dence interval), and also add that MTVpre as a
continuous variable is predictive of LR. In the cohort re-
ported by Ohri et al., a large subset of lesions with
MTVpre < 25 cc (34% of the total target lesions) received
< 60 Gy and there was no association between LR and
RT dose [11]. This prompted their prospective investiga-
tion of dose de-escalation for tumors with low MTVpre.
When evaluated in a small prospective study, this group
found low rates of local recurrence (3%) in low-risk le-
sions (MTVpre < 25 cc) treated with a reduced dose of
52.5–57 Gy, but high-risk lesions treated with conven-
tional RT had a higher risk of recurrence (9%) [14].
Others have also reported the prognostic utility of
pre-treatment tumor size in predicting LR including
a secondary analysis of RTOG 0235, which demon-
strated increasing total MTVpre (composite of all le-
sions) was significantly associated with LR [8].
Additionally, a large cohort from the Netherlands
found that tumor volume was the only significant
predictor of local recurrence [22]. This led to the
development of the PET-boost trial (NCT01024829)
which evaluated dose-escalation to entire primary tu-
mors or to regions of high pre-RT SUVmax within
the primary tumor but not involved lymph nodes
[19, 20]. However, given that lesion location was not
predictive of LR in our study, we hypothesize that
MTVpre and MTVmid, which are generally smaller
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for lymph nodes, are more reflective of the risk of
LR and therefore better biomarkers for dose-adapted
RT.
We identified that MTVmid may have greater predict-
ive utility compared with MTVpre and may provide add-
itional discrimination of lesions at risk for LR when
considered together with MTVpre. While MTVmid corre-
lates with initial tumor size and MTVpre, we hypothesize
that MTVmid contributes predictive information not cap-
tured in MTVpre. MTVmid may reflect the radioresistant
volume of tumors for which current definitive RT doses
are insufficient and inherent patient and tumor biologic
factors demonstrating worse response to treatment. A
prospective trial demonstrated an encouraging 2-year in-
field local control rate of 82% with mid-RT PET-CT in-
formed dose escalation to residual tumor with doses up
to 86 Gy. In this study, the rate of grade 3 radiation
pneumonitis was tolerable at 7% [15]. We await results
from the randomized RTOG 1106 in evaluating the
benefit of selective target volume dose escalation
(NCT01507428).
The question remains as to whether MTVpre and
MTVmid can predict LR better together versus indi-
vidually. We found that while MTVpre and MTVmid
were each highly predictive of LR, ΔMTV (MTVmid-
MTVpre)/MTVpre was not associated with LR. There
may be a more complicated relationship between
MTVmid and MTVpre in predicting tumor response,
which may depend on tumor histology, RT dose, and/
or timing of mid-RT PET-CT. Interestingly, a study
of patients with stage I-III NSCLC found that a
greater reduction in mid-RT MTV was associated
with worse survival in patients treated with conven-
tional RT, but improved survival in those treated with
PET-adapted dose escalation to the mid-RT residual
tumor volume. While counterintuitive, this lends fur-
ther support to the study of mid-RT PET-adapted RT
in RTOG 1106 [21].
To explore how to use both MTVpre and MTVmid
as biomarkers of LR, we investigated the predictive
utility of MTVmid in the high-risk (MTVpre ≥ 25 cc)
and low-risk (MTVpre < 25 cc). We found that
MTVmid was predictive of LR in the subset of low-
risk lesions with MTVpre < 25 cc. This suggests le-
sions with MTVpre < 25 cc that either resolve or
have significantly reduced MTVmid would be amen-
able for lower target dose as explored by others
[14]. In contrast, low-risk lesions with MTVpre < 25
cc and MTVmid ≥ 13.5 cc have a higher risk of local
recurrence and may not benefit from de-escalated
RT. Given the acceptable toxicity of dose escalation
to sites of residual FDG-avidity at mid-RT PET-CT,
these lesions, as well as those with MTVpre ≥ 25 cc,
may actually benefit from dose escalation [15]. In
future trials, MTVmid may be able to identify small,
seemingly low-risk lesions that are at increased risk
of local recurrence based on their underlying biol-
ogy and radiosensitivity. For example, in Ohri et al’s
prospective study of dose painting RT, 2 of the 3
low-risk lesions that recurred were presumed low
risk with very small MTVpre of 2 cc [14].
We did not find that MTVmid provided additional
prognostic utility for lesions already identified as
high risk for LR with MTVpre ≥ 25 cc. Given that
the threshold of MTVpre ≥ 25 cc was identified
based on the predictive capacity of MTVpre alone, it
is possible that we could determine better thresh-
olds leveraging information from MTVpre and
MTVmid. However, the low toxicity of higher RT
doses to individual sites defined as high-risk by
MTVpre and by FDG-avidity at mid-RT PET-CT
suggest that a higher RT dose to lesions with
MTVpre ≥ 25 cc may be associated with an accept-
able toxicity profile [11, 15].
Limitations of our analysis include its retrospect-
ive nature and fairly short follow-up time. Our re-
sults should be applied with caution to populations
that represented a minority of our dataset, such as
patients who did not receive chemotherapy. Many
patients in our series were treated to slightly higher
than standard dose per fraction (2.2Gy), which
could affect local recurrence rates. There may be
difficulties for other radiation oncology departments
to obtain mid-RT PET-CT scans. Finally, our spe-
cific MTV thresholds and rates of LR in our cohort
may not be representative for patients receiving ad-
juvant durvalumab, a treatment that became stand-
ard of care after the patients in our cohort were
treated. The patterns of failure for patients enrolled
in the PACIFIC trial were presented in abstract
form in 2019 but did not include detailed informa-
tion regarding the rate of ‘in-field’ recurrences after
RT [23]. Nevertheless, there was an 11.5% absolute
reduction in thoracic recurrences as first recur-
rences for patients receiving adjuvant durvalumab
compared with no further treatment, suggesting
local control may be improved with adjuvant im-
munotherapy. More detailed patterns of failure stud-
ies assessing recurrence location relative to
radiotherapy volumes for patients receiving defini-
tive chemoradiotherapy with adjuvant durvalumab
are required.
In summary, our results show larger MTVpre and
MTVmid are associated with increased risk of LR, and
MTVmid may hold higher predictive utility, particu-
larly in the setting of small lesions. If validated in lar-
ger cohorts, this may be the basis for designing
adaptive dose painting strategies to maximize
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therapeutic index. Specifically, our data support pro-
spective study of dose escalation to high-risk lesions
with MTVpre ≥ 25 cc. However de-escalation of le-
sions with MTVpre < 25 cc should be performed cau-
tiously, as lesions with more sluggish response
(MTVmid ≥ 13.5 cc) may have a higher risk of local
recurrence.
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